An accredited Developing
Stage business incubator
uk inspire Send this page | Bookmark | Print |

Business incubator for biotech and medtech startups

 

Diurnal appoints industry leading outsourced commercial services providers to support potential product launch in late 2017

Diurnal appoints industry leading outsourced commercial services providers to support potential product launch in late 2017

 


Diurnal Group plc who ae based at Cardiff Medicentre (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces significant progress in its commercial pre-launch activities following its first market authorisation submission for Infacort®to the European Medicines Agency (EMA) in December 2016, for which the Company anticipates market authorisation in late 2017.

As previously stated, Diurnal’s ambition is to market Infacort® itself in major European territories, thereby retaining the full commercial value of the product. Consistent with this strategy, Diurnal has signed a service agreement with Ashfield Healthcare (“Ashfield”), part of UDG Healthcare plc (LSE: UDG), to support the Company in building sales and medical infrastructure in major European territories. Ashfield is a respected global contract sales organisation that will focus in the next 12 months on establishing a Europe wide network of medical liaison staff to prepare the Company for the anticipated launch of Infacort® in 2018.

In addition, Diurnal has also signed an agreement with Sharp Packaging Services (“Sharp”), a global leader in contract packaging for the pharmaceutical and biotechnology industries, which is also part of UDG Healthcare, to bring expertise to ensure our Infacort® supply chain is managed by an internationally recognised expert business.

Together, these agreements provide the foundation for Diurnal’s supply chain to deliver the commercial product to Europe and other territories worldwide.

Dr Martin Whitaker, CEO of Diurnal, commented:

“Following the submission of our regulatory application for Infacort® to the EMA and its subsequent validation, we are focussed on pre-launch activities for this product in Europe. We are confident that the agreements announced today with Ashfield and Sharp, both leading providers of outsourced commercialisation services to the pharmaceutical industry, will help ensure the prompt and effective market introduction of Infacort® following its anticipated approval in Europe, another key step in realising our ambition of becoming the world’s leading specialty pharma company in endocrinology.”

For further information, please visit www.diurnal.co.uk or contact:

Diurnal Group plc     
Martin Whitaker, CEO  
Richard Bungay, CFO 
Tel: +44 (0)20 3727 1000

Numis Securities Ltd (Nominated Adviser)    
Nominated Adviser: Michael Meade, Freddie Barnfield,  Paul Gillam    
Corporate Broking: James Black    
Tel: +44 (0)20 7260 1000    

FTI Consulting     
Simon Conway    
Victoria Foster Mitchell
Tel: +44 (0)20 3727 1000 

Published on Tue, 21st Feb 2017

 
tenants
how to apply
directions

Follow us

  • RSS Feed